File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Phase II study of dasatinib in patients with previously treated malignant mesothelioma (Cancer and leukemia group B 30601): A brief report

TitlePhase II study of dasatinib in patients with previously treated malignant mesothelioma (Cancer and leukemia group B 30601): A brief report
Authors
Issue Date2012
Citation
Journal of Thoracic Oncology, 2012, v. 7 n. 4, p. 755-759 How to Cite?
AbstractINTRODUCTION: We conducted a phase II trial of dasatinib in malignant mesothelioma (MM) patients to evaluate its toxicity and efficacy as a second-line treatment. METHODS:: Patients with unresectable MM and no symptomatic effusions were given dasatinib 70 mg twice daily as part of a 28-day cycle. We also measured plasma vascular endothelial growth factor and platelet-derived growth factor b and colony stimulating factor 1 (CSF-1) and mesothelin-related protein at baseline and during therapy. RESULTS:: Forty-six patients were enrolled in this study. Fifty percent of the first 12 patients enrolled experienced grade 3 treatment-related adverse events, and therefore, the starting dose was reduced to 50 mg twice daily. Grade 3 and 4 toxicities included fatigue (11%) and pleural effusion (9%). The overall disease control rate was 32.6%, and progression-free survival at 24 weeks was 23% (95% confidence interval: 13.5-40.0%). Survival was markedly longer in patients with lower pretreatment CSF-1 levels and in patients whose CSF-1 levels decreased from baseline during therapy. DISCUSSION:: Single-agent dasatinib has no activity in MM and is associated with pulmonary toxicities that prohibit its use in an unselected MM population. © 2012 by the International Association for the Study of Lung Cancer.
Persistent Identifierhttp://hdl.handle.net/10722/194353
ISSN
2015 Impact Factor: 5.04
2015 SCImago Journal Rankings: 2.597
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorDudek, AZ-
dc.contributor.authorPang, H-
dc.contributor.authorKratzke, RA-
dc.contributor.authorOtterson, GA-
dc.contributor.authorHodgson, L-
dc.contributor.authorVokes, EE-
dc.contributor.authorKindler, HL-
dc.date.accessioned2014-01-30T03:32:29Z-
dc.date.available2014-01-30T03:32:29Z-
dc.date.issued2012-
dc.identifier.citationJournal of Thoracic Oncology, 2012, v. 7 n. 4, p. 755-759-
dc.identifier.issn1556-0864-
dc.identifier.urihttp://hdl.handle.net/10722/194353-
dc.description.abstractINTRODUCTION: We conducted a phase II trial of dasatinib in malignant mesothelioma (MM) patients to evaluate its toxicity and efficacy as a second-line treatment. METHODS:: Patients with unresectable MM and no symptomatic effusions were given dasatinib 70 mg twice daily as part of a 28-day cycle. We also measured plasma vascular endothelial growth factor and platelet-derived growth factor b and colony stimulating factor 1 (CSF-1) and mesothelin-related protein at baseline and during therapy. RESULTS:: Forty-six patients were enrolled in this study. Fifty percent of the first 12 patients enrolled experienced grade 3 treatment-related adverse events, and therefore, the starting dose was reduced to 50 mg twice daily. Grade 3 and 4 toxicities included fatigue (11%) and pleural effusion (9%). The overall disease control rate was 32.6%, and progression-free survival at 24 weeks was 23% (95% confidence interval: 13.5-40.0%). Survival was markedly longer in patients with lower pretreatment CSF-1 levels and in patients whose CSF-1 levels decreased from baseline during therapy. DISCUSSION:: Single-agent dasatinib has no activity in MM and is associated with pulmonary toxicities that prohibit its use in an unselected MM population. © 2012 by the International Association for the Study of Lung Cancer.-
dc.languageeng-
dc.relation.ispartofJournal of Thoracic Oncology-
dc.titlePhase II study of dasatinib in patients with previously treated malignant mesothelioma (Cancer and leukemia group B 30601): A brief report-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1097/JTO.0b013e318248242c-
dc.identifier.pmid22425926-
dc.identifier.scopuseid_2-s2.0-84858789713-
dc.identifier.volume7-
dc.identifier.issue4-
dc.identifier.spage755-
dc.identifier.epage759-
dc.identifier.isiWOS:000301866500018-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats